BridgeBio Pharma, Inc. BBIO
65.57
(0.71)
(1.07%)
as of 25 Sep
- Market cap
- $13.1B
- P/E
- 0.0×
Follow BBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
50.74% | 41.03% | 36.94% | 32.31% | |
| (95.85%) | (78.14%) | (64.06%) | (60.23%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(126.81%) | (140.72%) | (167.85%) | (333.08%) | |
Average Days of Receivables |
120.21 | 101.37 | 129.16 | 130.26 | |
Free Cash Flow per Share |
(3.12) | (2.38) | (2.29) | (2.22) | |
Free Cash Flow |
(597.75) | (455.55) | (445.12) | (435.39) | |
Capital Expenditures |
(12.93) | (9.64) | (1.17) | (1.01) | |
Piotroski F-Score |
4.00 | 2.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(101.85%) | (122.52%) | (74.20%) | (304.15%) | |
Accounts Receivable Turnover |
6.05 | 6.97 | 3.62 | 4.30 | |
Accounts Payable Turnover |
0.93 | 0.91 | 1.00 | 1.49 | |
Inventory Turnover |
0.00 | 0.00 | 1.53 | 1.12 | |
Average Days of Payables |
456.94 | 630.82 | 375.28 | 250.38 | |
Days of Inventory on Hand |
599.26 | 465.84 | 425.93 | 486.38 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
131.69% | 90.02% | 80.55% | 70.87% | |
Selling, General and Administrative Expense of Revenue |
132.26% | 105.81% | 101.52% | 90.58% | |
Share Based Compensation of Revenue |
36.33% | 26.49% | 24.21% | 20.65% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.62 | 0.62 | 0.63 | |
Depreciation/Fixed assets |
2.20 | 2.12 | 2.33 | 2.24 | |
Capex/Depreciation |
(1.01) | (0.85) | (0.10) | (0.09) | |
Revenue per Share |
1.84 | 2.62 | 2.98 | 3.64 | |
Operating CF per Share |
(3.05) | (2.33) | (2.28) | (2.22) | |
Capex per Share |
(0.07) | (0.05) | (0.01) | (0.01) | |
Capex to Sales |
0.04 | 0.02 | 0.00 | 0.00 | |
Net Profit Margin |
(225.31%) | (144.39%) | (124.41%) | (97.03%) |
Columns are period end dates